Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29970923 | 1.00 | TAAR1 (0.53) | TAAR1SIRT2FFAR1FFAR4L3MBTL1 | |
| SCHEMBL7109146 | 0.90 | TAAR1 (0.50) | TAAR1FFAR1FFAR4PTGES | |
| Phenyl Propionic Acid SCHEMBL28549085 | 0.90 | FFAR1 (0.59) | SIRT2FFAR1FFAR4L3MBTL1ESR1 | |
| SCHEMBL1743642 | 0.85 | FFAR1 (0.74) | FFAR1FFAR4ESR1NR3C1PGR | |
| SCHEMBL1511063 | 0.84 | CYP4F2 (0.55) | TAAR1FFAR1FFAR4L3MBTL1ESR1 | |
| SCHEMBL15504971 | 0.83 | SIRT2 (0.51) | SIRT2PTPN1 | |
| SCHEMBL26714888 | 0.83 | FFAR1 (0.50) | TAAR1FFAR1FFAR4L3MBTL1ESR1 | |
| SCHEMBL29700723 | 0.83 | SLC7A5 (0.55) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL136054 | 0.83 | SLC7A5 (0.55) | TAAR1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL902744 | 0.83 | L3MBTL1 (0.47) | TAAR1FFAR1FFAR4L3MBTL1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115637275-A | Preparation method of (S) -2- (4-bromophenyl) propionic acid | 天津药明康德新药开发有限公司 | 2023-01-24 | — | — | CN | claimed |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | ROTTAPHARM BIOTECH S.R.L. (IT) | 2025-12-30 | — | — | US | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2024-09-12 | — | — | US | disclosed |
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | disclosed |
| WO-2007089667-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089667-A1 | COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1802630-A2 | TRITYL DERIVATIVES FOR ENHANCING MASS SPECTROMETRY | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2007-07-04 | — | — | EP | disclosed |
| WO-2007002557-A1 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO., INC. | 2006-12-28 | — | — | US | disclosed |
| WO-2006032893-A2 | TRITYL DERIVATIVES FOR ENHANCING MASS SPECTROMETRY | OXFORD GENE TECHNOLOGY IP LIMITED (GB) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | TAAR1 1221/4885SIRT2 1623/4885FFAR1 2816/4885 |
| US-20060293364-A1 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | HCAR1, HCAR2, FFAR1 | TAAR1 73/4885SIRT2 207/4885FFAR1 3/4885 |
| US-12509446-B2 | FYN and VEGFR2 kinase inhibitors | FYN, LCK, LYN | TAAR1 1746/4885SIRT2 2265/4885FFAR1 883/4885 |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | TAAR1 3199/4885SIRT2 1580/4885FFAR1 501/4885 |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | TAAR1 4633/4885SIRT2 4106/4885FFAR1 4383/4885 |
| US-20240299559-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | CDK2, SKP2, CDK1 | TAAR1 4570/4885SIRT2 2407/4885FFAR1 4638/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | TAAR1 977/4885SIRT2 1731/4885FFAR1 289/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | TAAR1 167/4885SIRT2 727/4885FFAR1 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.